Compare Alphabet Inc Class A (GOOGL) vs 10X Genomics Inc (TXG) Price & Performance

Alphabet (GOOGL) trades at $348.29, down 0.63% on the day, with strong technical support at $346 and resistance at $352. The company demonstrates robust fundamentals with 2025 revenue of $402.84B and net income of $132.17B, achieving a 32.8% profit margin. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $9.11 surpassing the $2.87 estimate. Analyst consensus remains overwhelmingly bullish with 87% buy ratings and a $431.83 price target, representing 24% upside potential.

Alphabet presents a compelling investment case driven by AI leadership, strong cash flow generation, and consistent earnings outperformance. Key risks include regulatory scrutiny, competitive pressures in search and cloud, and market volatility. The stock's current valuation at 17.48x P/E appears reasonable given growth prospects, while technical indicators suggest near-term consolidation within a defined trading range.

TXG trades at $77.28, up 1.55% on the day, showing resilience despite a bearish technical signal. The company's fundamentals are improving, with revenue reaching $642.82M in 2025 and net losses narrowing significantly to -$43.54M. Recent news highlights strong demand for its Atera spatial biology platform and a favorable patent verdict. However, valuation metrics like a P/S of 15.99 and EV/EBITDA of 249.22 remain elevated, reflecting high growth expectations.

The outlook is cautiously optimistic. The primary opportunity lies in the commercial success of new platforms like Atera and Sentira driving future profitability. Key risks include the high valuation requiring flawless execution, ongoing losses, and competitive pressures in the life sciences tools sector. Analyst sentiment is mixed, with a near-even split between Buy and Hold ratings and a consensus price target slightly below the current price.